Thrombotic microangiopathy after carfilzomib in a very young myeloma patient
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 81, 102400
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Late Presentation of Carfilzomib Associated Thrombotic MicroangiopathyAmerican Journal of Medical Case Reports, 2019
- Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletionBlood Advances, 2018
- Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatmentClinical Case Reports, 2017
- Proteasome inhibitor associated thrombotic microangiopathyAmerican Journal of Hematology, 2016
- Carfilzomib: A cause of drug associated thrombotic microangiopathyTransfusion and Apheresis Science, 2016
- Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myelomaAnnals of Hematology, 2015
- Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchangeJournal of Clinical Apheresis, 2014
- Syndromes of Thrombotic MicroangiopathyNew England Journal of Medicine, 2014
- Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic SyndromePLOS Genetics, 2007